Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib in Previously Treated KRAS G12C-Mutated Advanced NSCLC
2021-006958-31Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Gustave Roussy. Primary endpoint: Tumor response at 4 months and resistance biomarkers. Started Apr 2022; status: active.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-006958-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006958-31.